STOCK TITAN

Cormedix - CRMD STOCK NEWS

Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.

Cormedix Inc (CRMD) is a clinical-stage biopharmaceutical company pioneering novel therapies for life-threatening infectious and inflammatory conditions. This news hub provides investors and healthcare stakeholders with essential updates on DefenCath developments, regulatory milestones, and therapeutic pipeline progress.

Access timely announcements including FDA correspondence, clinical trial data, and commercialization strategies for CRMD's catheter lock solutions. Our curated collection features earnings reports, partnership disclosures, and scientific presentations relevant to infection prevention in critical care settings.

Key updates cover therapeutic candidate advancements, intellectual property developments, and market expansion initiatives. Monitor progress in addressing bloodstream infections through CRMD's specialized antimicrobial formulations designed for high-risk patient populations.

Bookmark this page for structured access to verified corporate communications and analysis of how CRMD navigates the complex biopharmaceutical regulatory landscape. Stay informed on developments impacting both patient care standards and long-term therapeutic innovation.

Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) has resubmitted its New Drug Application (NDA) for DefenCath to the FDA, addressing previously noted deficiencies in a Complete Response Letter. DefenCath is designed to reduce catheter-related bloodstream infections in patients undergoing chronic hemodialysis. The company's third-party manufacturer has also responded to necessary changes identified by the FDA. The FDA will review the resubmission for completeness within 30 days, and a preapproval inspection may be required.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.39%
Tags
none
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) announced participation in multiple upcoming investor conferences in January 2022. Key events include:

  • LifeSci Partners – January 5-7
  • H.C. Wainwright Bioconnect Virtual Conference – January 10-13
  • Biotech Showcase Virtual Conference – January 10-12

CorMedix focuses on developing therapeutic products, notably DefenCath™, for preventing life-threatening infections related to central venous catheters in hemodialysis patients. The FDA has designated DefenCath as Fast Track and QIDP, offering extended marketing exclusivity upon NDA approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
conferences
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) reported its third quarter 2021 financial results, announcing a net loss of $8.6 million or $0.22 per share, compared to a loss of $6.6 million in Q3 2020. The increase in losses was attributed to a 30% rise in operating expenses, primarily due to heightened manufacturing costs for DefenCath. Despite challenges, manufacturing activities have resumed, and the company aims to resubmit its NDA. With $72 million in cash, CorMedix believes it can fund operations through 2022. A conference call is scheduled for November 9, 2021 to further discuss developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
Rhea-AI Summary

CorMedix Inc. (CRMD) announced it will report its Q3 financial results on November 9, 2021, following the market close. The company specializes in developing therapeutic products for infectious and inflammatory diseases, with a focus on its lead product, DefenCath. This product aims to prevent bloodstream infections related to central venous catheters in chronic hemodialysis patients. DefenCath has received FDA Fast Track designation and QIDP status for marketing exclusivity. However, the company also noted it received a Complete Response Letter from the FDA due to deficiencies at its manufacturing facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) announced the acceptance of three abstracts for presentation at major conferences, focusing on catheter-related bloodstream infections (CRBSIs) in hemodialysis patients. Key highlights include:

  • 29% of ~56,000 hemodialysis patients experienced CRBSI after central venous catheter (CVC) insertion.
  • 54% of first CRBSIs occurred within three months of CVC insertion.
  • Annual costs of $2.3 billion from CVC-related infections were estimated.

Dr. Matt David emphasized the importance of these findings in addressing the high incidence of CRBSIs and the potential of DefenCath to reduce these infections by approximately 71%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) has announced significant changes in its executive leadership. Khoso Baluch has retired as CEO effective October 4, 2021, alongside John Armstrong, EVP for Technical Operations. Matt David, the current EVP and CFO, has been appointed as interim CEO while the Board initiates a search for a permanent replacement. Baluch will assist as an advisor during the transition. The changes aim to maintain momentum in advancing CorMedix’s key product, DefenCath, which is under FDA review for its potential to prevent infections in hemodialysis patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
management
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) announced delays in its DefenCath New Drug Application (NDA) due to issues at its third-party manufacturer. These issues are unrelated to the manufacturing of DefenCath, and the timeline for addressing deficiencies is currently uncertain. DefenCath is designed to prevent bloodstream infections in hemodialysis patients and has received Fast Track designation from the FDA. The company has committed to conducting a pediatric clinical study upon NDA approval, which could extend marketing exclusivity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.45%
Tags
none
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) reported a net loss of $4.6 million for Q2 2021, versus $3.8 million in Q2 2020, attributed to higher personnel costs and lower tax benefits. Despite a 34% reduction in operating expenses to $5.9 million, SG&A expenses rose 4% to $3.4 million. Cash reserves are robust at $78.3 million, expected to cover operations through 2022. The company aims to address FDA deficiencies and plans to re-submit its DefenCath™ NDA by Q4 2021. CorMedix emphasizes its commitment to delivering an antimicrobial solution for hemodialysis patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.39%
Tags
-
Rhea-AI Summary

CorMedix Inc. (Nasdaq: CRMD) will announce its second-quarter financial results on August 12, 2021, following market close, and hold a conference call at 4:30 PM ET. The company is focused on its lead product, DefenCath™, which aims to prevent infections in patients with central venous catheters during hemodialysis. DefenCath has received Fast Track designation and was granted a Qualified Infectious Disease Product status by the FDA, allowing for additional marketing exclusivity upon NDA approval. Investors may gain insights into upcoming clinical studies and financial outlook during the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences earnings
Rhea-AI Summary

CorMedix Inc. (CRMD) announced the completion of a $1.3 million sale of tax benefits to a profitable New Jersey corporation through the New Jersey Technology Business Tax Certificate Transfer program for FY 2020. This program allows unprofitable technology firms to convert net operating losses into cash. The funding received will support CorMedix's growth, particularly for research and development. The company is also advancing its lead product, DefenCath™, aimed at preventing bloodstream infections in patients with central venous catheters.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
Cormedix

Nasdaq:CRMD

CRMD Rankings

CRMD Stock Data

530.58M
60.43M
1.25%
39.99%
12.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS